News headlines about GW Pharmaceuticals PLC (NASDAQ:GWPH) have been trending positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. GW Pharmaceuticals PLC earned a media sentiment score of 0.27 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 33 out of 100, meaning that recent press coverage is unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern’s analysis:
- Gw Pharmaceuticals Plc (GWPH) Stake Increased by Farallon Capital Management Llc, Marcato Capital Management … – BZ Weekly (bzweekly.com)
- How Analysts Rated GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Last Week? – WeeklyHub (weeklyhub.com)
- GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Expects Its New … – MMJ Reporter (mmjreporter.com)
- Pura Vida Investments Has Lifted Holding in Gw Pharmaceuticals … – BZ Weekly (bzweekly.com)
- This is what analysts have to say about GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) after last week. – Weekly Register (weeklyregister.com)
Several equities analysts recently weighed in on GWPH shares. BidaskClub upgraded GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday. Maxim Group set a $135.00 price target on GW Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Thursday, June 8th. TheStreet lowered GW Pharmaceuticals PLC from a “c-” rating to a “d+” rating in a research note on Wednesday, May 10th. Zacks Investment Research lowered GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Monday, May 15th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $208.00 price target on shares of GW Pharmaceuticals PLC in a research note on Tuesday, May 9th. Two research analysts have rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $144.50.
GW Pharmaceuticals PLC (NASDAQ GWPH) traded up 0.87% during midday trading on Friday, reaching $103.81. The company had a trading volume of 167,963 shares. GW Pharmaceuticals PLC has a 1-year low of $79.62 and a 1-year high of $137.88. The firm’s 50 day moving average is $103.62 and its 200 day moving average is $115.89. The stock’s market capitalization is $2.63 billion.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.50) by $0.20. GW Pharmaceuticals PLC had a negative return on equity of 22.81% and a negative net margin of 1,021.38%. The firm had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $2.07 million. During the same period in the prior year, the company earned ($0.06) earnings per share. The company’s revenue for the quarter was down 23.0% on a year-over-year basis. On average, equities analysts anticipate that GW Pharmaceuticals PLC will post ($5.34) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “GW Pharmaceuticals PLC (GWPH) Receiving Positive Media Coverage, Report Finds” was published by sleekmoney and is the sole property of of sleekmoney. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://sleekmoney.com/gw-pharmaceuticals-plc-gwph-receiving-positive-media-coverage-report-finds/1935961.html.
GW Pharmaceuticals PLC Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/gw-pharmaceuticals-plc-gwph-receiving-positive-media-coverage-report-finds/1935961.html
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.